Quantitative Determination and Validation of Ivabradine HCL by Stability Indicating RP-HPLC Method and Spectrophotometric Method in Solid Dosage Form
 
More details
Hide details
1
Department of Pharmaceutical Analysis, B.R.Nahata College of Pharmacy, Mhow Neemach Road, Mandsaur, Madhya Pradesh, India
2
Analytical Development Laboratory, Zydus Cadila Healthcare Limited Sarkhej Bavla N.H-8A, Changodar, Ahemdabad-3821210, Gujarat, India
CORRESPONDING AUTHOR
Shweta Maheshwari   

Department of Pharmaceutical Analysis, B.R.Nahata College of Pharmacy, Mhow Neemach Road, Mandsaur, Madhya Pradesh, India
Publish date: 2017-10-05
 
Eurasian J Anal Chem 2010;5(1):53–62
KEYWORDS
ABSTRACT
A highly sensitive, selective, reproducible, rapid and stability indicating RP-HPLC and spectrophotometric method has been developed and validated successfully for analysis of a new anti angina agent Ivabradine HCL in solid dosage form. Separation and detection of Ivabradine HCL by HPLC was achieved by Inertsil ODS-3V [250 mm * 4.6mm] 5m column and U.V. detector at l 286 nm respectively. In HPLC method the retention time was about 7 minutes. Complete validation study for both the methods was carried out according to ICH guideline. Linearity of both the methods was achieved in the range 4.2 to 31.6 µg mL-1 with a correlation coefficient (r2) ≥ 0.999. The limit of detection and the limit of quantification were 0.06 µg mL-1and 0.2 µg mL-1respectively. The intra-day and inter-day precision and accuracy values for both methods were within the assay variables as per the ICH guideline. The HPLC method can be used for the routine quantitative determination and stability study of Ivabradine HCL in Pharmaceutical dosage forms, since it proved to be stability indicating also.
 
REFERENCES (9)
1.
Klippert P, Jeanniot JP, Polve S, Lefevre C, Merjan H (1998) Determination of ivabradine and its N-demethylated metabolite in human plasma and urine, and in rat and dog plasma by a validated high-performance liquid chromatography method with fluorescence detection, Journal of chromatography B, 719: 125-133.
 
2.
Bouchard FM, Simonin G, Bossant JM, and Neyret BC (2000) Simultaneous determination of ivabradine and its metabolites in human plasma by liquid chromatography-tandem mass spectroscopy, Journal of Chromatography B, 745: 261- 269.
 
3.
Du XJ, Feng X, Gao XM, Tan TP, Kiriazis H, Dart A M (2004) If channel inhibitor ivabradine lowers heart rate in mice, British J. Of Pharmacology, 142: 107-112.
 
4.
Heusch G (2008) Pleiotropic action(s) of the bradycardic agent ivabradin cardiovascular protection beyond heart rate reduction', Br. J. of Pharmacology, 347.
 
5.
Tardi CJ, Ford I, Tendera M, Martial G, Bourassa, Kim F (2005) Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina, European Heart J 26: 2529-2536.
 
6.
Evans ND, Godfrey KR, Chapman M J, Aarons L and Duffull S B (2001) An Identifiability Analysis of a Parent–Metabolite Pharmacokinetic Model for Ivabradine, J. Pharmacokinetics and Pharmacodynamics, 28:93.
 
7.
ICH Q1A (R2) (2003) Stability Testing of New Drug Substances and Products. International Conference on Harmonisation, IFPMA, Geneva.
 
8.
ICH Q1B (1996) Stability Testing of New Drug Substances and Products. International Conference on Harmonisation, IFPMA, Geneva.
 
9.
ICH Q2B (2005) Stability Testing of New Drug Substances and Products. International Conference on Harmonisation, IFPMA, Geneva.
 
eISSN:1306-3057